Chris at R&D Directions Insider blog spoke with both Merck's Alan Sachs and Amgen's Sean Harper down at the BIO meeting in Atlanta. Sachs is a VP of RNA Therapeutics and tells Chris that Merck isn't focusing on the delivery of RNA-based drugs but instead is looking whether RNA-based drugs make be safely taken for a chronic condition.